These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16548765)

  • 1. Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.
    Pavlakis N; Vogelzang NJ
    Expert Opin Biol Ther; 2006 Apr; 6(4):391-9. PubMed ID: 16548765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.
    Beck AK; Pass HI; Carbone M; Yang H
    Future Oncol; 2008 Jun; 4(3):341-9. PubMed ID: 18518759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell.
    Drugs R D; 2007; 8(2):120-4. PubMed ID: 17324010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
    Mikulski SM; Costanzi JJ; Vogelzang NJ; McCachren S; Taub RN; Chun H; Mittelman A; Panella T; Puccio C; Fine R; Shogen K
    J Clin Oncol; 2002 Jan; 20(1):274-81. PubMed ID: 11773179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
    Vogelzang NJ; Aklilu M; Stadler WM; Dumas MC; Mikulski SM
    Invest New Drugs; 2001; 19(3):255-60. PubMed ID: 11561684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.
    Costanzi J; Sidransky D; Navon A; Goldsweig H
    Cancer Invest; 2005; 23(7):643-50. PubMed ID: 16305992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.
    Porta C; Paglino C; Mutti L
    Biologics; 2008 Dec; 2(4):601-9. PubMed ID: 19707441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribonucleases as novel chemotherapeutics : the ranpirnase example.
    Lee JE; Raines RT
    BioDrugs; 2008; 22(1):53-8. PubMed ID: 18215091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.
    Lee I
    Expert Opin Biol Ther; 2008 Jun; 8(6):813-27. PubMed ID: 18476793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Onconase: a ribonuclease with antitumor activity].
    Zwolińska M; Smolewski P
    Postepy Hig Med Dosw (Online); 2010 Feb; 64():58-66. PubMed ID: 20173221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
    Guazzelli A; Bakker E; Tian K; Demonacos C; Krstic-Demonacos M; Mutti L
    Expert Opin Investig Drugs; 2017 Aug; 26(8):933-944. PubMed ID: 28679291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K; Garey JS
    Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly efficient destruction of squamous carcinoma cells of the head and neck by photochemical internalization of Ranpirnase.
    Liebers N; Holland-Letz T; Welschof M; Høgset A; Jäger D; Arndt MAE; Krauss J
    J Exp Ther Oncol; 2017 Nov; 12(2):113-120. PubMed ID: 29161778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
    Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
    Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.
    Altomare DA; Rybak SM; Pei J; Maizel JV; Cheung M; Testa JR; Shogen K
    BMC Cancer; 2010 Feb; 10():34. PubMed ID: 20137089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for malignant pleural mesothelioma.
    Janne PA
    Clin Lung Cancer; 2003 Sep; 5(2):98-106. PubMed ID: 14596692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB.
    Tsai SY; Ardelt B; Hsieh TC; Darzynkiewicz Z; Shogen K; Wu JM
    Int J Oncol; 2004 Dec; 25(6):1745-52. PubMed ID: 15547713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of pemetrexed for the treatment of malignant mesothelioma.
    Kindler HL
    Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):49-53. PubMed ID: 15339060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.